povidone-iodine gel (IVIEW-1201) / IVIEW Therap - LARVOL DELTA

Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: IVIEW Therapeutics Inc. | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Keratitis • Ocular Inflammation • Ophthalmology

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis (clinicaltrials.gov) - P2 | N=135 | Completed | Sponsor: IVIEW Therapeutics Inc. | Trial completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis (clinicaltrials.gov) - P2 | N=129 | Completed | Sponsor: IVIEW Therapeutics Inc. | Trial completion date: Oct 2023 ➔ Oct 2024

Trial completion date • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: IVIEW Therapeutics Inc.

New P2 trial • Keratitis • Ocular Inflammation • Ophthalmology

Development of a Long-Lasting In-situ Gel-Forming Solution for the Treatment of Conjunctivitis (ARVO 2024) - "IVIEW-1201 is an in-situ gel-forming povidone iodine composition which results in long-lasting anti-viral and antimicrobial efficacy."

Conjunctivitis • Corneal Abrasion • Ocular Infections • Ocular Inflammation • Ophthalmology

A Phase II, Multi-Center, Blinded, Randomized, Parallel-Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone Iodine) Gel Forming Ophthalmic Solution Compared to Ofloxacin Eye Drops in the Treatment of Acute Bacterial Conjunctivitis. (ARVO 2024) - P2 | "IVIEW-1201 appeared to have similar clinical efficacy to treat acute bacterial conjunctivitis compared with Ofloxacin. The clinical cure rate of IVIEW-1201 may be higher than Ofloxacin. The safety of IVIEW-1201 is in line with our expectation and appeared well tolerated."

Clinical • P2 data • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis (clinicaltrials.gov) - P2 | N=135 | Completed | Sponsor: IVIEW Therapeutics Inc. | Recruiting ➔ Completed

Trial completion • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis (clinicaltrials.gov) - P2 | N=129 | Completed | Sponsor: IVIEW Therapeutics Inc. | Not yet recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Oct 2023 | Initiation date: Jun 2023 ➔ Jan 2023 | Trial primary completion date: Dec 2024 ➔ Sep 2023

Trial completion • Trial completion date • Trial initiation date • Trial primary completion date • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology